Q1 2025 Management View CEO Eric Langan highlighted key developments, including increases in Nightclub segment sales and same-store sales. Bombshells segment sales declined due to closures of ...
Arrowhead Pharmaceuticals (NASDAQ:ARWR) reported a larger-than-expected loss for Q1 FY2025, with earnings per share (EPS) at -$1.39, missing the forecast of -$0.39. Revenue also fell short, totaling ...